Stoke Therapeutics announced that the Food and Drug Administration (FDA) has postponed a decision on the company’s request for an expedited submission of its treatment for severe epilepsy. The request pertains to zorevunersen, which is designed to address Dravet syndrome, a severe form of epilepsy that typically begins in infancy.
In a meeting held in December 2023, the FDA did not outright reject Stoke’s appeal to submit the drug for review this year. Instead, the agency has requested additional information before making a determination. Ian Smith, CEO of Stoke Therapeutics, provided details in an interview, expressing optimism that further discussions are on the horizon.
The FDA’s current stance means that Stoke may have to wait until the ongoing Phase 3 study concludes, which is not expected until the middle of 2027. This timeline poses a challenge for the company as it seeks to bring this critical treatment to market sooner. The FDA’s feedback indicates that while there is a possibility for an earlier review, the path forward remains uncertain.
Stoke anticipates making a definitive decision regarding its regulatory strategy for zorevunersen by mid-2024. The company remains committed to collaborating with the FDA to provide the necessary data and facilitate the approval process.
This development emphasizes the complexities involved in bringing new treatments to market, particularly for rare and severe conditions such as Dravet syndrome. As Stoke continues its dialogue with the FDA, the future of zorevunersen will depend on the additional information provided and the outcomes of ongoing studies.
Overall, this situation highlights the critical balance between regulatory oversight and the urgent need for effective therapies for patients with severe epilepsy.
